ArticleThe Psychopharmacology of Fragile X SyndromeErickson, Craig A. MD; Stigler, Kimberly A. MD; Posey, David J. MD; McDougle, Christopher J. MD Author Information Dr. Erickson is Fellow in Child and Adolescent Psychiatry, Dr. Stigler is Assistant Professor of Psychiatry, Dr. Posey is Associate Professor of Psychiatry, and Dr. McDougle is Albert E. Sterne Professor and Chairman, Department of Psychiatry, Indiana University School of Medicine, 702 Barnhill Drive, Room 4300, Indianapolis, IN 46202; E-mail: [email protected]. Dr. Erickson has disclosed that he receives grant/research support from Bristol-Myers Squibb. Dr. Stigler has disclosed that she is/was the recipient of grant/research support from Bristol-Myers Squibb and Janssen. Dr. Posey has disclosed that he is/was the recipient of grant research support from and is/was a consultant for Forest, and that he is/was a stock shareholder of Shire. Dr. McDougle has disclosed that he is/was the recipient of grant/research support from Bristol-Myers Squibb and Janssen; is/was a consultant advisor for Bristol-Myers Squibb; was a consultant/advisor for Eli Lilly; is a consultant advisor Forest; is/was a member of the speakers bureau for Bristol-Myers Squibb and Janssen; and was a member of the speakers bureau for Pfizer. The authors also have disclosed that, except for risperidone in youths ages 5–17 with autism and associated irritability, none of the medication uses discussed in this article have been approved by the U.S. Food and Drug Administration. This article was supported by a grant from the FRAXA Research Foundation (Drs. Erickson and McDougle) and a Pilot Research Award (Dr. Erickson) from the American Academy of Child & Adolescent Psychiatry. International Drug Therapy Newsletter 42(5):p 35-42, May 2007. | DOI: 10.1097/01.IDT.0000268048.57852.41 Buy CME Test Metrics © 2007 Lippincott Williams & Wilkins, Inc.